
The immunoglobulin E (IgE) receptor FcεRI undergoes dynamic changes in response to allergens (i.e., Ags; antigens) and IgE properties. Mast cell (MC) responses to high-affinity (dinitrophenyl [DNP]-Fab) and low-affinity (nitrophenyl [2NP]-Fab) Ags demonstrated that affinity differences between Ag and IgE determine subsequent cellular reactions. This study assessed Ag-IgE affinity effect on Ag-induced FcεRI desensitization efficacy and safety. Murine bone marrow-derived MCs (BMMCs) were sensitized using anti-DNP IgE, treated with increasing DNP-Ag and 2NP-Ag concentrations, and subsequently challenged with optimal DNP-Ag concentration. We observed that 2NP-Ag induced FcεRI internalization without MC activation. Both Ags can desensitize FcεRI in BMMCs, with DNP-Ag activating MCs during desensitization, whereas 2NP-Ag achieved FcεRI desensitization without MC activation. IgE-FcεRI cluster response to foreign Ags initiates MC outcomes. The formation of small IgE-FcεRI clusters is crucial for gradual and silent FcεRI internalization. In this study, low-affinity Ag-IgE stimulation forms small IgE-FcεRI clusters, contributing to effective FcεRI desensitization. These results indicate that Ag-IgE affinity is essential for FcεRI desensitization safety.
ABSTRACT Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune‐mediated platelet destruction and impaired thrombopoiesis. While immune dysfunction has been extensively studied, the role of the bone marrow microenvironment—particularly extracellular matrix (ECM) mechanics—remains underexplored. Evidence from haematopoietic and immune systems indicates that ECM stiffness and remodelling can influence immune‐cell activity and megakaryocyte function through mechanotransduction pathways including integrin–FAK, YAP/TAZ and mechanosensitive ion‐channel signalling. This review summarizes current knowledge of ECM mechanical regulation in immune and haematopoietic processes and discusses how aberrant ECM cues may contribute to ITP pathogenesis. We also discuss supportive mechanistic insights from related autoimmune and fibrotic diseases, outline key knowledge gaps and propose future research directions including biomechanical profiling of the ITP marrow niche and development of ECM‐targeted therapies. Understanding the mechanobiological regulation of immune and stromal interactions may open new therapeutic avenues for ITP.
ABSTRACT Hepatocellular carcinoma (HCC) undergoes profound metabolic reprogramming, yet the specific lipid species responsible for driving immunosuppressive remodelling remain unclear. BODIPY 493/503 and Oil Red O staining were used to assess the lipid accumulation in macrophages treated with tumour‐conditioned medium. Immunofluorescence analysis was performed to visualize lipid droplets, while qPCR and flow cytometry were conducted to evaluate the expression of CD36, CD163, CD206 and PD‐L1 on macrophages. Transmission electron microscopy assay was applied to observe mitochondrial morphology and fission. Fatty acid screening was performed to identify the CD36‐mediated signalling pathway. In vivo validation was performed using a DEN/CCl 4 ‐induced HCC mouse model treated with oleic acid alone or in combination with the CD36 inhibitor SSO. We demonstrate that lipid‐rich conditioned medium from HCC cells (HCC‐CM) promotes CD36‐associated intracellular lipid accumulation in tumour‐associated macrophages (TAMs). This lipid accumulation drives M2 polarization, mitochondrial fission and upregulation of PD‐L1 expression in TAMs and is associated with impaired CD8 + T‐cell effector function. Among six representative fatty acids screened, oleic acid emerged as the strongest candidate and recapitulated these effects through CD36‐dependent lipid uptake, mitochondrial remodelling and PD‐L1 upregulation. SSO co‐treatment attenuated these effects both in vitro and in a DEN/CCl 4 ‐induced primary liver cancer model, where it was associated with improved CD8 + T‐cell effector function and reduced tumour growth. Our findings identify oleic acid as a key lipid mediator in TAM reprogramming and highlight CD36 as a potential therapeutic target to restore antitumour immunity in HCC.
ABSTRACT Colorectal cancer (CRC) remains a major cause of cancer‐related morbidity and mortality worldwide, with its progression and therapeutic resistance increasingly recognized as consequences of complex metabolic and immune interactions within the tumour microenvironment (TME). Recent advances in single‐cell and spatial multi‐omics technologies have enabled detailed characterisation of metabolic heterogeneity among TME components, uncovering how distinct metabolic states influence immune function and therapeutic responses. In this review, we summarize recent advances in our understanding of metabolic regulation in the CRC microenvironment, with a particular focus on how distinct immune cell populations contribute to tumour progression and immune suppression through diverse metabolic pathways. We discuss key metabolite‐driven signalling networks involving lactate, short‐chain fatty acids, bile acids, and amino acid derivatives, and examine how these pathways influence immune cell function and tumour‐immune interactions. Furthermore, we highlight emerging therapeutic approaches targeting the metabolic‐immune axis, including glutaminase inhibitors, CD36 antagonists, and combination regimens integrating metabolic intervention with immune checkpoint inhibitors. By integrating recent mechanistic discoveries with therapeutic perspectives, this review provides an updated overview of the metabolic‐immune landscape in CRC and discusses potential strategies to exploit metabolic vulnerabilities for improving immunotherapy efficacy and overcoming treatment resistance.